A40AEG Pentixapharm Holding AG

EQS-News: Pentixapharm Welcomes CMS Decision to Enhance Reimbursement for Diagnostic Radiopharmaceuticals

EQS-News: Pentixapharm Holding AG / Key word(s): Statement
Pentixapharm Welcomes CMS Decision to Enhance Reimbursement for Diagnostic Radiopharmaceuticals

04.11.2024 / 17:26 CET/CEST
The issuer is solely responsible for the content of this announcement.


Berlin and Würzburg, Germany, November 4, 2024 – Pentixapharm, a biopharmaceutical company developing innovative first-in-class radiopharmaceuticals, welcomes the recent announcement by the U.S. Centers for Medicare & Medicaid Services (CMS) to implement separate payments for specialized diagnostic radiopharmaceuticals used in the hospital outpatient setting, extending beyond the transitional pass-through payment period. This significant policy shift could have a direct impact on future reimbursement streams for Pentixapharm’s Ga68-PentixaFor, a diagnostic radiopharmaceutical for which Pentixapharm intends to start a U.S. centric phase III clinical trial next year. The pivotal clinical trial could lead to a U.S. market authorization in primary aldosteronism (PA), one of the major causes of secondary hypertension, as early as 2028.

The CMS pass-through payment period is a temporary reimbursement mechanism under the Hospital Outpatient Prospective Payment System (OPPS). Lasting up to three years, this period provides additional payments for newly introduced medical devices, drugs, and biologicals, encouraging hospitals to adopt cutting-edge technologies by covering their costs beyond standard rates. However, under previous policies, after the pass-through period ended, products would typically revert to standard OPPS payment bundles. With this new policy announcement, CMS has changed this approach, allowing for separate payments beyond the pass-through period for qualifying high-cost diagnostics.

This decision by CMS is highly significant given the size and impact of the Medicare and Medicaid systems, which together insure more than 140 million Americans. As the primary healthcare payer for older adults and individuals with disabilities, CMS’s reimbursement policies shape access to medical innovations across the country. The new rule, effective in 2025, also has the potential to set a market precedent that may influence private insurers to follow CMS’s lead in reimbursing innovative diagnostic tools, further expanding the accessibility of these advanced diagnostics. By providing consistent reimbursement for diagnostic radiopharmaceuticals that exceed a per-day cost threshold of US$630, CMS encourages other insurers to consider similar reimbursement strategies.

The separate payment rule will most likely apply to Pentixapharm's lead diagnostic compound, Ga68-PentixaFor, following its anticipated approval and the expiration of its pass-through status. Ga68-PentixaFor is a novel tracer for positron emission tomography (PET) imaging used to detect aldosterone-hypersecreting adenomas in patients diagnosed with primary Aldosteronism (PA). With rising prevalence rates for PA, now exceeding 20% in some populations with resistant hypertension, the need for accessible and precise diagnostics is greater than ever.

About Pentixapharm

Pentixapharm is a clinical-stage biotech company discovering and developing novel targeted radiopharmaceuticals with its offices in Berlin and Würzburg, Germany. It is committed to developing CXCR4 ligand-based first-in-class radiopharmaceutical approaches with a clear commercial pathway for diagnostic and therapeutic programs in a number of hematological and solid cancers, as well as cardiovascular, endocrine and inflammatory diseases.

PentixaFor (Gallium (68Ga) boclatixafortide) is an innovative PET tracer that specifically targets the chemokine-4 receptor (CXCR4), with broad applications in oncological, cardiovascular, and inflammatory diseases. Particularly in hypertension, PentixaFor has the potential to significantly improve patient management by identifying the presence of hormone-secreting adenomas through non-invasive and broadly available PET/CT imaging.

Apart from PentixaFor, the clinical pipeline also encompasses PentixaTher, an Yttrium-90 or Lutetium-177 based therapeutic against non-Hodgkin lymphomas (NHL). Clinical studies for both compounds have already commenced in Europe, including a dose-finding study for PentixaTher and a Phase III registration study for PentixaFor in marginal zone lymphoma. Recently, the EMA granted PRIME status to PentixaFor in the indication PA.

For more information, please contact:

Pentixapharm Holding AG
Phillip Eckert, Investor Relations

Tel.



04.11.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com


Language: English
Company: Pentixapharm Holding AG
Robert-Rössle-Straße 10
13125 Berlin
Germany
E-mail:
Internet: /
ISIN: DE000A40AEG0
WKN: A40AEG
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2022121

 
End of News EQS News Service

2022121  04.11.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=2022121&application_name=news&site_id=research_pool~~~9efe1c65-8ece-4ff7-9608-f21c8e0a38a3
EN
04/11/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pentixapharm Holding AG

Dr. Roger Becker
  • Dr. Roger Becker

Further important indication - First patient in treatment

Note regarding MiFID II: This research report has been prepared by order of the issuer based on a contractual agreement and is being compensated for by the issuer. The research report has simultaneously been made publicly available to all interested persons. Hence, the receipt of this research report is to be regarded as a permitted insignificant non-monetary benefit according to § 64 para 7 sentence 2 No. 1 and 2 of the German Securities Trading Act (WpHG). Pentixapharm Holding AG (ISIN DE00...

Dr. Roger Becker
  • Dr. Roger Becker

Weitere bedeutende Indikation – Erster Patient in Behandlung

MiFID II – Hinweis: Diese Studie wurde auf Grundlage einer vertraglichen Vereinbarung im Auftrag des Emittenten erstellt und von diesem vergütet. Die Studie wurde gleichzeitig allen Interessenten öffentlich zugänglich gemacht. Der Erhalt dieser Studie gilt somit als zulässiger geringfügiger nichtmonetärer Vorteil im Sinne des § 64 Abs. 7 Satz 2 Nr. 1 und 2 des WpHG. Mit der heutigen Meldung gibt die Pentixapharm Holding AG (ISIN DE000A40AEG0, Prime Standard, PTP GY) bekannt, dass der erste vo...

 PRESS RELEASE

EQS-News: Erster Patient in Phase I/II Studie zu akuter myeloischer un...

EQS-News: Pentixapharm Holding AG / Schlagwort(e): Studie Erster Patient in Phase I/II Studie zu akuter myeloischer und akuter lymphoblastischer Leukämie mit Lu177-PentixaTher behandelt, Stärkung der Datenlage für gezielte Radiotherapie 21.11.2024 / 11:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Berlin und Würzburg, 21. November 2024 – Die Pentixapharm Holding AG, ein biopharmazeutisches Unternehmen, das innovative Radiopharmazeutika entwickelt, gab heute bekannt, dass der erste Patient in einer Phase-I/II-Studie behandelt wurd...

 PRESS RELEASE

EQS-News: First Patient Treated in Phase I/II Trial in Acute Myeloid a...

EQS-News: Pentixapharm Holding AG / Key word(s): Study First Patient Treated in Phase I/II Trial in Acute Myeloid and Acute Lymphoblastic Leukemia with Lu177-PentixaTher, Expanding the Evidence Base for Targeted Radiotherapy Approach 21.11.2024 / 11:00 CET/CEST The issuer is solely responsible for the content of this announcement. Berlin and Würzburg, Germany, November 21, 2024 – Pentixapharm Holding AG, a biopharmaceutical company developing innovative first-in-class radiopharmaceuticals, today announced that the first patient has been treated in a Phase I/II clinical tr...

 PRESS RELEASE

EQS-News: Pentixapharm veröffentlicht Zwischenbericht für das 3. Quart...

EQS-News: Pentixapharm Holding AG / Schlagwort(e): Quartals-/Zwischenmitteilung Pentixapharm veröffentlicht Zwischenbericht für das 3. Quartal 2024 12.11.2024 / 17:45 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Pentixapharm veröffentlicht Zwischenbericht für das 3. Quartal 2024 Verlust der Pentixapharm Holding AG im Berichtszeitraum: 49 Tsd. € Keine Umsatzrealisierung im Rumpfgeschäftsjahr bis Ende Q3 Kurzfristige Verbindlichkeiten von 487 Tsd. €, hauptsächlich aus Aktienkauf der Pentixapharm AG Berlin und Würzburg, 12. Novembe...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch